News just out. Look at the VRI depth!!!!!
SUCCESSFUL COMPLETION OF FIRST STAGE OF ANTI-INFLAMMATORY MOLECULE
DISCOVERY PROGRAM
VRI has had a successful result in the first stage of its anti-inflammatory molecule discovery program - confirming
that PCC® (VRI’s probiotic strain) inhibits inflammatory responses.
After human clinical trials indicated that PCC® (a complex organism) may have anti-inflammatory effects, VRI
commissioned the Rowett Research Institute (RRI) in the UK to conduct a 2-stage program to:
1. Confirm that PCC® is capable of inhibiting inflammation and to determine the mechanism of that action at
both gene and protein levels.
2. Identify the molecule(s) responsible for the anti-inflammatory activity.
The successful stage 1 outcome means that VRI can now commit to stage 2 which is likely to yield results before
the end of 2005.
A successful outcome of stage 2 will be the discovery of one or more novel anti-inflammatory molecule(s) derived
from PCC®. This would be extremely valuable intellectual property which VRI would license to a major
pharmaceutical company for development and marketing.
This level of scientific discovery is unique in the probiotics industry, and should increase VRI’s attraction to
licensing partners.
Inflammatory diseases (including Inflammatory Bowel Disease, Rheumatoid Arthritis, Atherosclerosis, and
Chronic Obstructive Pulmonary Disease) afflict one in three people in developed countries.
The recent problems associated with $multi-billion selling COX-2 inhibitors such as Vioxx and Celebrex make this
area of R&D of great interest to the large pharmaceutical companies.
The report from the RRI Chief Investigator Dr Denise Kelly, concluded that PCC® induced significant antiinflammatory
activity at the higher doses at both gene and protein levels.
Furthermore, the data suggest that molecules on the PCC® bacteria are capable of inhibiting a range of different
inflammatory pathways, indicating that their inhibitory effect may have broad specificity and application in
inflammatory disease.
The report provides evidence that the anti-inflammatory activity is confined to the bacterial membrane, and is not
secreted. Some pro-inflammatory activity was detected in the conditioned media, which was inhibited by the
higher concentrations of PCC® bacteria.
VRI BioMedical Ltd
is bringing science to wellness by
commercialising a range of
products for health maintenance and
disease prevention, based on robust
scientific and clinical research.
VRI BioMedical has developed
extensive intellectual property
in three platform technologies:
probiotics diagnostics vaccines
VRI BioMedical Ltd
ACN 084 464 193 ABN 97 084 464 193
Suite G09, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney NSW 1430, Australia
Phone: +61 2 9209 4268 Fax: +61 2 9209 4256
www.vribiomedical.com.au
ABOUT VRI BIOMEDICAL
VRI Biomedical Limited (ASX Code: VRI) is an Australian biopharmaceutical company specialising in the
development and commercialisation of its world leading probiotic technology.
In 2004 VRI launched its proTractTM range of gastrointestinal products in Australian pharmacies and has since
negotiated distribution/licensing agreements in other countries.
FOR MORE INFORMATION CONTACT:
CEO: Mr Kim Slatyer (02) 9209 4268
Innovation & Business Development Manager: Dr Peter French (02) 9209 4228
- Forums
- ASX - General
- about to blast off!!!!!!!!!!!!!!!
about to blast off!!!!!!!!!!!!!!!
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)